Lovaza

ApprovedSmall molecule

AstraZeneca

Lovaza is one of 609 small molecule programs targeting Arrhythmia. It is currently in Approved.

Indications

Total Trials

Active Trials

608

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArrhythmiaActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

LymphomaActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Chest PainActive, not recruiting

Congestive Heart FailureActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

ImmunodeficiencyActive, not recruiting

PancreatitisActive, not recruiting

ArrhythmiaApproved

Active, not recruiting

Cardiovascular DiseasePhase 2

Active, not recruiting

Non-Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Acute Myocardial InfarctionPhase 1/Phase 2

Active, not recruiting

Chest PainPreclinical

Active, not recruiting

Congestive Heart FailurePhase 3

Active, not recruiting

Peripheral Arterial DiseasePreclinical

Active, not recruiting

ImmunodeficiencyApproved

Active, not recruiting

PancreatitisPhase 1

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lovaza

AstraZeneca

Approved

4 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer4 trials

Breast Cancer Risk Biomarkers in Premenopausal Women

Completed·—·Phase 2·NCT01252277·36 enrolled

COGNUTRIN in Breast Cancer Survivors

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01823991·36 enrolled

Breast Cancer Risk Biomarkers in Postmenopausal Women

Completed·—·Phase 2·NCT01252290·35 enrolled

Show 1 more trial

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03175666

Hypertriglyceridemia3 trials

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

Withdrawn·UUniversity of Utah·Phase 4·NCT01180764

Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia

Completed·MMassachusetts General Hospital·Phase 4·NCT00833976·65 enrolled

Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia

Completed·SSanford Research·Phase 1/2·NCT00959842·15 enrolled

Pancreatic Cancer2 trials

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03329248·6 enrolled

QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387098·4 enrolled

Liver Disease2 trials

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

Withdrawn·—·Phase 1/2·NCT01191177

Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation

Unknown status·UUniversity of Tennessee·N/A·NCT01157780·100 enrolled

Inflammation2 trials

Fish Oils and Adipose Inflammation Reduction

Completed·UUniversity of Pennsylvania·Phase 4·NCT02010359·29 enrolled

Pro-Resolving Mediators in Acute Inflammation in Humans

Completed·—·Phase 1·NCT04308889·19 enrolled

25 more indications

Endotoxemia1 trial

Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia

Completed·UUniversity of Pennsylvania·N/A·NCT01048502·100 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Cardiovascular Disease1 trial

Pilot Placebo Controlled Study With Lovaza in Cardiovascular Disease

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT01001767·35 enrolled

Peripheral Arterial Disease1 trial

Lovaza Therapy of Peripheral Arterial Disease

Withdrawn·UUniversity of Virginia·N/A·NCT00569686

Pancreatitis1 trial

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02189252·30 enrolled

Non-Small Cell Lung Cancer1 trial

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169738

Vascular Function1 trial

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

Completed·TTufts University·Phase 4·NCT01041521·129 enrolled

Chest pain1 trial

Women With Chest Pain and Normal Coronary Arteries Study

Terminated·NNorthwestern University·N/A·NCT00743197·3 enrolled

Immunodeficiency1 trial

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

Completed·TTufts University·Phase 4·NCT00795717·41 enrolled

ISS1 trial

Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue

Withdrawn·MMilton S. Hershey Medical Center·Phase 1·NCT01784042

Delayed Onset Muscle Soreness1 trial

The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers

Completed·WWestern Michigan University·Phase 2·NCT00805870·20 enrolled

Outcome1 trial

Pulmonary Vein Isolation Outcomes With Fish Oils

No longer available·SSt. Luke's-Roosevelt Hospital Center··NCT00841451

Congestive Heart Failure1 trial

The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure

Terminated·—·Phase 3·NCT00944229·58 enrolled

Current Smoker1 trial

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03598309·19 enrolled

Diabetic Foot1 trial

Immunonutrition for Diabetic Foot Ulcers

Terminated·PPrisma Health-Midlands·Phase 2/3·NCT05281562·1 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Acute Myocardial Infarction1 trial

The Effects of Lovaza® in Acute Myocardial Infarction

Terminated·UUniversity of Rochester·Phase 1/2·NCT01155336·4 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

Unknown status·HHuntington Medical Research Institutes·Phase 4·NCT00941642·40 enrolled

Arrhythmia1 trial

Effects of Fish Oil on Post Ablation Arrhythmias

Terminated·UUniversity of Michigan·Phase 4·NCT00791089·12 enrolled

Adolescent1 trial

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

Terminated·—·Phase 2·NCT00672633·25 enrolled

Type 2 Diabetes1 trial

Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM

Completed·WWashington University School of Medicine·N/A·NCT00577590·78 enrolled

Resistance1 trial

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

Completed·UUniversity of Rochester·Phase 1/2·NCT00771914·27 enrolled

Lymphoma1 trial

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169790

Colorectal Cancer1 trial

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169777

Unspecified1 trial

Lovaza's Effect on the Activation of Platelets

Completed·IInvitrox·Phase 2·NCT00515541·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 38 trial records for Lovaza. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lovaza compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lovaza. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AstraZeneca

Lovaza

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer4 trials

Hypertriglyceridemia3 trials

Pancreatic Cancer2 trials

Liver Disease2 trials

Inflammation2 trials

Endotoxemia1 trial

Urothelial Cancer1 trial

Cardiovascular Disease1 trial

Peripheral Arterial Disease1 trial

Pancreatitis1 trial

Non-Small Cell Lung Cancer1 trial

Vascular Function1 trial

Chest pain1 trial

Immunodeficiency1 trial

ISS1 trial

Delayed Onset Muscle Soreness1 trial

Outcome1 trial

Congestive Heart Failure1 trial

Current Smoker1 trial

Diabetic Foot1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Acute Myocardial Infarction1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Arrhythmia1 trial

Adolescent1 trial

Type 2 Diabetes1 trial

Resistance1 trial

Lymphoma1 trial

Colorectal Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News